products

Thyroid Cancer Chemical Raw Materials Selumetinib CAS 606143-52-6 With COA

Basic Information
Place of Origin: CHINA
Brand Name: MOSINTER
Certification: COA
Model Number: Antineoplastic Drugs API - 71
Minimum Order Quantity: 1KG
Price: Negotiation
Packaging Details: Aluminum foil bag, fiber can, kraft paper bag
Delivery Time: Within 7 days
Supply Ability: Can be customized according to customer requirements
Detail Information
Name: Selumetinib CAS: 606143-52-6
Appearance: Powder Molecular Formula: C17H15BrClFN4O3
Molecular Weight: 457.685 Purity: 99%
High Light:

chemical raw materials

,

pharmaceutical raw materials


Product Description

Selumetinib CAS 606143-52-6 Pharmaceutical Grade Chemicals
 

Description:

 

Selumetinib (AZD6244) is a drug that was discovered by Array BioPharma and was licensed to AstraZeneca. It is being investigated for the treatment of various types of cancer, such as non-small cell lung cancer (NSCLC) and thyroid cancer.The gene BRAF is part of the MAPK/ERK pathway, a chain of proteins in cells that communicates input from growth factors. Activating mutations in the BRAF gene, primarily V600E (meaning that the amino acid valine in position 600 is replaced by glutamic acid), are associated with lower survival rates in patients with papillary thyroid cancer. Another type of mutation that leads to undue activation of this pathway occurs in the gene KRAS and is found in NSCLC. A possibility of reducing the activity of the MAPK/ERK pathway is to block the enzyme MAPK kinase (MEK), immediately downstream of BRAF, with the drug selumetinib. More specifically, selumetinib blocks the subtypes MEK1 and MEK2 of this enzyme.

 

Specifications:

 

Product Name: Selumetinib
CAS Number: 606143-52-6
Molecular Weight: 457.685
Molecular Formula: C17H15BrClFN4O3
Specification: 99%
Appearance: White powder

 

Application:

 

Treatment of neurofibromas in those with neurofibromatosis. In addition to thyroid cancer, BRAF-activating mutations are prevalent in melanoma (up to 59%), colorectal cancer (5–22%), serous ovarian cancer (up to 30%), and several other tumor types. Selumetinib has also been shown to inhibit growth of GNAQ mutated uveal melanoma cell lines. Furthermore, preliminary results suggest that selumetinib treatment of uveal melanoma patients can result in tumor shrinkage as the consequence of sustained inhibition of ERK phosphorylation.

 

Our strengths:
 
We can customize according to customer's requirement.
If you have any question pls mail us or call us.

 

Contact Details
Fedor

Phone Number : +86 18989305995

WhatsApp : +18989305995